Ziraoui, Nour-Eddine and Okafor, Chinedu and Asantewaa, Yaa (2026) HIGH-PURITY SILYMARIN FLAVONOLIGNANS AND METABOLIC LIVER HEALTH: COMPOSITION STANDARDIZATION AND TRANSLATIONAL EVIDENCE. EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE, 6 (8). ISSN 2795-921X

Text 1788070804_17488dab326998dabe87.pdf Download (361kB)

Abstract

Silymarin is a chemically heterogeneous mixture of flavonolignans, and differences in composition and formulation can complicate interpretation of its clinical effects. This study characterized a standardized NVTIA® high-purity silymarin flavonolignan composition and considered its profile in relation to published human evidence on liver injury and metabolic liver disease. Three optimized preparations contained 82.1–83.4% total silymarin and 39.4–40.6% combined silybin A+B, with yields of 5.3–5.6% and residual deep-eutectic-solvent components of 0.27–0.31%. Targeted process comparators produced lower total silymarin contents (68.4–77.1%) when solvent switching, resin enrichment, or antisolvent crystallization was omitted. Randomized studies in non-cirrhotic NASH/MASLD have produced mixed results for composite histologic activity, although some trials have reported favorable fibrosis-related or biochemical findings. Meta-analyses likewise suggest reductions in aminotransferases across heterogeneous liver-injury populations. These observations support a practical formulation principle: a reproducible flavonolignan profile should be established before clinical effects are attributed to a specific preparation. Future studies can build on this foundation by relating verified silymarin and silybin exposure to contemporary measures of liver stiffness, fibrosis, and histologic activity.

Item Type:	Article
Uncontrolled Keywords:	silymarin, silybin, milk thistle, flavonolignans, hepatocellular protection, MASLD, NASH, liver function
Subjects:	H Social Sciences
Depositing User:	admin eprints
Date Deposited:	05 Nov 2026 08:30
Last Modified:	05 Nov 2026 08:30
URI:	http://eprints.umsida.ac.id/id/eprint/17482

Actions (login required)

View Item